Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

72.95EUR
19 Jan 2018
Change (% chg)

€0.58 (+0.80%)
Prev Close
€72.37
Open
€72.37
Day's High
€73.17
Day's Low
€72.21
Volume
2,264,166
Avg. Vol
2,131,108
52-wk High
€92.97
52-wk Low
€71.06

Select another date:

BRIEF-Sanofi appoints new EVP, in charge of business transformation

* says appoints Dominique Carouge as executive vice president head of business transformation and member of the executive committee, effective Feb. 15 Further company coverage: (Paris Newsroom)

LPC-Bankers line up €1.2bn debt for Sanofi’s European drugs unit sale

LONDON, Jan 18 Bankers have put together around €1.2bn of debt financing to back a potential sale of French drug maker Sanofi’s European generic drug business as the sale process kicks off, banking sources said.

BRIEF-Stada Agrees To Early Termination Of License Agreement With Sanofi

* STADA AGREES TO EARLY TERMINATION OF LICENSE AGREEMENT WITH SANOFI FOR HEAD LICE LOTION HEDRIN Further company coverage: (Gdynia Newsroom)

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS, Jan 8 France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

BRIEF-Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 Palisade Trial Of AR101 For Peanut Allergy

* AIMMUNE THERAPEUTICS - PALISADE COMPLETED IN 2017; TOPLINE RESULTS ANTICIPATED IN FEBRUARY

BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership

* AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE

Sanofi to market new hemophilia drug in deal with Alnylam

PARIS, Jan 8 French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals.

BRIEF-Evotec, Apeiron Biologics receive milestone payment from Sanofi

* SAYS ‍EVOTEC AND APEIRON ACHIEVE FIRST MILESTONE IN IMMUNO-ONCOLOGY ALLIANCE WITH SANOFI​

Philippines fines Sanofi, suspends clearance for Dengvaxia

MANILA The Philippines has fined Sanofi $2,000 and suspended clearance for the French drug maker's controversial dengue vaccine Dengvaxia, citing violations on product registration and marketing, its health secretary said on Thursday.

Select another date: